Campbell & CO Investment Adviser LLC Makes New $393,000 Investment in Emergent Biosolutions Inc. $EBS

Campbell & CO Investment Adviser LLC purchased a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 44,608 shares of the biopharmaceutical company’s stock, valued at approximately $393,000. Campbell & CO Investment Adviser LLC owned 0.08% of Emergent Biosolutions as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Millennium Management LLC raised its stake in Emergent Biosolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after purchasing an additional 1,020,582 shares during the period. Geode Capital Management LLC grew its holdings in Emergent Biosolutions by 108.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,278,998 shares of the biopharmaceutical company’s stock valued at $8,162,000 after buying an additional 666,708 shares in the last quarter. Bank of America Corp DE raised its position in shares of Emergent Biosolutions by 232.1% during the second quarter. Bank of America Corp DE now owns 309,947 shares of the biopharmaceutical company’s stock valued at $1,977,000 after buying an additional 216,630 shares during the last quarter. Prescott Group Capital Management L.L.C. lifted its holdings in shares of Emergent Biosolutions by 23.1% in the second quarter. Prescott Group Capital Management L.L.C. now owns 772,771 shares of the biopharmaceutical company’s stock worth $4,930,000 after buying an additional 145,100 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Emergent Biosolutions by 17.0% in the second quarter. Acadian Asset Management LLC now owns 974,590 shares of the biopharmaceutical company’s stock worth $6,216,000 after buying an additional 141,274 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.

Insiders Place Their Bets

In other Emergent Biosolutions news, Director Ronald Richard sold 21,984 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $11.97, for a total value of $263,148.48. Following the completion of the sale, the director directly owned 98,417 shares in the company, valued at approximately $1,178,051.49. This represents a 18.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on EBS. Weiss Ratings reiterated a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Emergent Biosolutions in a report on Tuesday, December 16th. Zacks Research raised Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. Finally, Wall Street Zen raised Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 30th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $15.00.

Emergent Biosolutions Stock Up 5.0%

NYSE EBS opened at $12.08 on Friday. Emergent Biosolutions Inc. has a 52 week low of $4.02 and a 52 week high of $14.06. The firm has a market capitalization of $634.44 million, a price-to-earnings ratio of 9.29 and a beta of 2.30. The company has a quick ratio of 3.15, a current ratio of 5.76 and a debt-to-equity ratio of 1.14. The company has a fifty day moving average of $11.74 and a two-hundred day moving average of $9.65.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $1.18. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The business had revenue of $231.10 million during the quarter, compared to the consensus estimate of $203.67 million. On average, analysts predict that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.